CD47 is an antiphagocytic signal that cancer cells employ to inhibit macrophagemediated destruction. Here, we modified the binding domain of human SIRPα, the receptor for CD47, for use as a CD47 antagonist. We engineered high-affinity SIRPα variants with approximately 50,000-fold increased affinity for human CD47 relative to wild-type SIRPα. As high-affinity SIRPα monomers, they potently antagonized CD47 on cancer cells but did not induce macrophage phagocytosis on their own. Instead, they exhibited remarkable synergy with all tumor-specific monoclonal antibodies tested by increasing phagocytosis in vitro and enhancing antitumor responses in vivo. This "one-two punch" directs immune responses against tumor cells while lowering the threshold for macrophage activation, thereby providing a universal method for augmenting the efficacy of therapeutic anticancer antibodies.
Immune evasion is an emerging hallmark of cancer (1) , and therapies that direct immune responses against cancer show promise in experimental and clinical settings (2, 3) . Macrophages commonly infiltrate tumors, and their tumoricidal potential can be harnessed to benefit patients (4). CD47 is an antiphagocytic "don't eat me" signal that distinguishes live cells from dying or aged cells, inhibits Fc receptor-mediated functions by myeloid cells, and is highly expressed by many cancers to avoid detection by macrophages (5) (6) (7) (8) (9) (10) (11) (12) (13) . Antibodies that block binding of CD47 to SIRPα, an inhibitory receptor on macrophages, greatly increase phagocytosis of cancer cells (9, 10, 12, 13) . However, antibodies have limited tissue distribution and can exert off-target effects (14, 15) .
To improve CD47-targeted therapies, we used the single 14 kDa binding domain of human SIRPα as a competitive antagonist to human CD47 ( fig. S1A ). Due to the weak ~1 μM affinity of the native SIRPα-CD47 interaction (16) (17) (18) , however, we found that wild-type SIRPα was a poor antagonist. To improve the affinity of human SIRPα for human CD47, we created mutant libraries of the N-terminal V-set Ig domain of SIRPα (residues 1-118) conjugated to Aga2p for yeast surface-display ( fig. S1B ). Using the CD47 Ig superfamily (IgSF) domain as a selection reagent, we conducted two 'generations' of in vitro evolution using yeast surface display (figs. S1 and S2 and Fig. 1A ). We obtained variants that bound CD47 with dissociation constants (K D ) as low as 34.0 pM and dissociation half-lives (t 1/2 ) as long as 44 min compared to 0.3-0.5 μM K D and 1.8 s t 1/2 for wild-type SIRPα (Fig. 1A) . The sequences of the high-affinity SIRPα variants converged on a consensus set of mutations. When we grafted these nine conservative substitutions onto the predominant wild-type human SIRPα allele (19) (allele 2), the resulting variant (termed CV1, consensus variant 1) bound human CD47 with an affinity of 11.1 p.m. (Fig. 1A) .
We determined the crystal structure of the high-affinity variant FD6 bound to the human CD47 IgSF domain (Fig.  1B, fig. S3 , and table S1). The FD6:CD47 complex superimposed with the wild-type SIRPα:CD47 complex (17) with a root mean square deviation of only 0.61 Å, indicating a high degree of structural similarity and validating our efforts to preserve the geometry of the wild-type interaction (Fig. 1C) . The overlapping binding modes of FD6 and wild-type SIRPα indicate they would compete for the same CD47 epitope, providing maximal antagonism. As notable differences, the FD6 binding interface appears stabilized by three mutations in the C′D loop (Fig. 1C , lower inset) and the Ile31Phe mutation (Fig. 1C, upper inset) . These structural studies imply the high-affinity SIRPα variants could serve as efficacious CD47 antagonists.
When assessed for their ability to antagonize CD47 on the surface of human cancer cells, we found that SIRPα variants with increased CD47 affinity exhibited greater potency in binding ( fig. S4 , A and C) and blocking cell-surface CD47 ( Fig. 2A and fig.  S4B ). As single-domain monomers ( fig.  S5A ), both FD6 and CV1 exhibited potent antagonism relative to wild-type SIRPα. Subsequently, we evaluated the ability of high-affinity SIRPα variants to increase phagocytosis in vitro by co-culturing macrophages and tumor cells in the presence of CD47-blocking agents. As fusion proteins to the Fc fragment of human IgG4 (hIgG4) ( fig. S5, A and B) , the high-affinity SIRPα variants led to increased phagocytosis of cancer cells as measured by microscopy and flow cytometry (Fig. 2B, fig. S6 , and movies S1 and S2). No substantial phagocytosis was observed upon treatment with high-affinity SIRPα monomers, with dimers lacking Fc chains, or with B6H12 Fab fragments at concentrations that maximally antagonize CD47 (Fig. 2, B to D, fig.  S5 , C and D, and fig. S7 ). Thus phagocytosis was only observed when CD47 was blocked in the presence of antibody Fc chains, which contribute a necessary pro-phagocytic stimulus.
Consequently, we hypothesized that treatment with high-affinity SIRPα monomers would enhance phagocytosis in the presence of tumorspecific monoclonal antibodies. Thus, we performed phagocytosis assays using antibodies targeting DLD-1 colon cancer cells. Indeed, highaffinity SIRPα monomers significantly augmented phagocytosis when combined with a nonblocking anti-CD47 antibody (20) or an antiEpCam antibody, but not an isotype control (Fig. 2C) .
To demonstrate the clinical implications of this principle, we examined the ability of high-affinity SIRPα monomers to enhance the efficacy of established antibodies currently used as cancer therapies. Phagocytosis assays were performed using Her2/neu + SK-BR-3 breast cancer cells (21) . Baseline phagocytosis was observed with SIRPα monomers alone, while treatment with the therapeutic anti-Her2/neu antibody trastuzumab alone or with wild-type SIRPα monomer led to moderate increases in phagocytosis (Fig. 2D) . However, the combination of trastuzumab with high-affinity SIRPα monomers FD6 or CV1 resulted in maximal levels of phagocytosis that were higher than the additive effect of either agent administered alone. Similar effects were observed with the anti-EGFR antibody cetuximab using DLD-1 cells and with Raji lymphoma cells treated with varying concentrations of rituximab, an anti-CD20 antibody ( fig. S7, A and B) . Using a panel of recombinant anti-CD20 antibodies that contain the rituximab variable region and differing heavy chain isotypes, we found that CV1 monomer was able to augment phagocytosis in response to all human IgG subclasses ( fig. S7C) . Therefore, the high-affinity SIRPα monomers could act as universal adjuvants to tumor-specific antibodies.
We next evaluated these principles in vivo by investigating the activity of the high-affinity SIRPα variants in mouse tumor models. We engrafted human tumors into NSG (NOD scid gamma) mice, which lack functional T, B, and NK cells but retain functional macrophages (10, 12, 22) . NSG mice express a SIRPα allele that binds human CD47 and inhibits macrophage activity, thereby enabling in vivo evaluation of human CD47 blockade (10, 12, 19, (23) (24) (25) . We tested CV1-hIgG4 in a model of human bladder cancer to determine whether a single molecule combining a high-affinity SIRPα domain with a pro-phagocytic signal could act as a single agent for cancer. GFP-luciferase + 639-V bladder cancer cells were subcutaneously engrafted into NSG mice. Treatment with CV1-hIgG4 inhibited tumor growth (Fig. 3, A and B) and produced a significant benefit in survival even after discontinuing treatment (Fig.  3C) . In CV1-hIgG4 treated mice, palpable stromal tissue developed around the sites of tumor engraftment that contained small tumor nodules embedded in an inflammatory infiltrate containing macrophages with evidence of phagocytosis ( fig. S8) .
Although wild-type human SIRPα does not bind mouse CD47, the high-affinity SIRPα variants acquired cross-reactivity with mouse CD47 (fig. S10) . Thus, our in vivo models allow for evaluation of efficacy in the presence of a large 'antigen sink' and toxicity due to CD47 expression on normal mouse cells. Examination of the blood of treated animals revealed that CV1-hIgG4 coated all mouse blood cells ( fig. S9A ) and resulted in the development of chronic anemia as a side effect of therapy ( fig. S9, B and C) . No toxicity to other blood lineages was observed ( fig.  S9C ). Red blood cell loss has also been observed with anti-mouse CD47 antibodies (12) , consistent with these findings.
We further examined the safety of the high-affinity SIRPα variants in a toxicity study with cynomolgus macaques, which express a CD47 ortholog that is nearly identical to human CD47 ( fig. S11, A and B) . A single low-dose (1.5 mg/kg) injection of high-affinity SIRPα-Fc into two independent animals produced a substantial drop in red blood cells (fig. S11, C and D), similar to our findings in mice. By contrast, no hematologic toxicity was observed in an animal treated with a dose escalation of high-affinity SIRPα monomer from 0.3 mg/kg to 10 mg/kg. No toxicity to other blood lineages or organ systems was detected in any of the animals, nor did we detect evidence of anaphylaxis ( fig. S11, D and E) . These findings further demonstrate that a single molecule that blocks CD47 and contains a pro-phagocytic stimulus, such as antibody Fc chains, produces toxicity. We therefore surmised that the high-affinity SIRPα monomers plus use of an independent antibody may offer an alternative and improved strategy for targeting CD47.
To explore the in vivo potential of the high-affinity SIRPα monomers, combination with rituximab was evaluated in a localized model of Raji cell lymphoma. Eight days post-engraftment ( fig. S12A ), mice received a three-week course of daily treatment with either vehicle, CV1 monomer alone, rituximab alone, or a combination of rituximab plus CV1 monomer. Treatment with CV1 monomer or rituximab alone only slowed tumor growth, whereas the combination therapy completely eliminated tumors in the majority of mice and the effects persisted after treatment was stopped (Fig. 4, A to D, and fig. S12B ). During the course of treatment, no toxicity to red blood cells or other hematologic lineages was observed (fig. S13 ). The effects of each therapy translated to respective trends in survival (Fig. 4D) . The combination therapy remained effective against large Raji tumors ( fig. S14, A and B) . Additionally, we administered the high-affinity SIRPα monomers in combination with alemtuzumab (anti-CD52), a second therapeutic antibody targeting Raji lymphoma cells (26) . Combination therapy significantly inhibited tumor growth and increased survival ( fig. S15) . Together, these findings validate our strategy as a safe and effective approach to antagonizing CD47 and provide a proof-of-concept demonstration that the high-affinity SIRPα monomers can augment the efficacy of therapeutic antibodies in vivo.
We performed immunohistochemical staining of the large Raji tumors after treatment to examine macrophage infiltration. Compared to rituximab alone, tumors receiving combination treatment showed extensive macrophage infiltration ( fig. S14, C and D) . The extent of macrophage infiltration and therapeutic efficacy in vivo paralleled the degree of phagocytosis in vitro by NSG mouse macrophages ( fig. S14E ). Together, these findings indicate that macrophages are effector cells for the CV1 monomer/rituximab therapy, as has previously been confirmed for rituximab and anti-CD47 antibodies (9, 10) .
In a third model, Her2/neu + BT474M1 breast cancer cells were engrafted into the mammary tissue of female NSG mice, and tumors were allowed to grow to approximately 1 cm in diameter (~200 mm 3 ) (Fig.  4E) . Treatment with CV1 monomer alone had no effect on tumor growth, whereas trastuzumab alone was able to reduce tumor volume over time (Fig. 4F) . The addition of CV1 monomer to the antibody regimen enhanced tumor regression (Fig. 4F) , consistent with the results observed with rituximab and alemtuzumab.
Our findings support a new model for the action of CD47-targeting agents ( fig. S16 ). As observed with high-affinity SIRPα monomers, blockade of CD47 alone does not induce macrophage activation, but instead lowers the threshold for phagocytosis. The combination of highaffinity SIRPα monomers with an independent, tumor-specific antibody directs macrophage attack against cancer cells without toxicity to normal cells expressing CD47. Due to their immense potential as targeted therapies, over one hundred antibodies are under clinical investigation (27) . While antibodies have demonstrated considerable clinical success thus far, they often elicit limited responses, and relapse is common following treatment (28-30). We have developed reagents that broadly enhance the efficacy of tumor-specific antibodies and thus could act as universal adjuvants to antibody therapies. Overall, this study deepens our knowledge of macrophage responses to malignant cells and supports further evaluation of the high-affinity SIRPα reagents as immunotherapies for cancer. Eight to ten mice per group were treated and analyzed, and each data point represents a measurement from an independent mouse. Tumor volumes for all cohorts were measured at the same time points (data are staggered for clarity). Bars indicate median values. (A to F) Black arrows indicate the start and stop of the treatment period. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 for antibody alone versus combination therapy, or as indicated otherwise, by Kruskal-Wallis with Dunn's correction (A and C) or Mann-Whitney test with Bonferroni correction for the indicated comparisons (F).
